HC Pharma
ActiveSummary
HC Pharma has been active since 1961 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (-€992,548) and a net result of -€235,534. Equity is growing by ~4.7% per year across the filed fiscal years. Its solvency ranks better than 9% of 10485 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.5% (very low).
Checked score
Score 2025
Axes · tick = 2024
Profitability63▼-5
Solvency5▼-3
Growth58▼-20
Track record100
Bankruptcy probability, 12 months
0.5%
Very low
0%0.5%1.5%4%10%≥ 25%
No credit on open account
Liquidity short (current ratio 0.2 against 0.23 in 2024; short-term debt: 120.2% and cash: 0.1% of total assets), and equity is negative.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Five signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Retail trade (NACE 47)
about 45% more bankruptcies
← fewer bankruptcies
more bankruptcies →
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
-20.2%
Return on assets
-4.8%
Age of the figures
9 mo
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025Equity per financial year
1819202122232425
2018 to 2025 · latest year -€992,548
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 12-05-2026, 80 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
80 d early
2024
45 d early
2023
50 d early
2022
52 d early
2021
54 d early
2020
47 d early
2019
18 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 49 days before the deadline; the sector median for financial year 2024 is on the deadline day, and 46% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
27-09-2026 today31-12-2026 close31-07-2027 deadline
History
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check What other support did companies like this one receive, and it did not?Public money Which other companies belong to the same group?PHARMACIE BIA · 40 companies
Is this your company? See how customers and banks see it.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2025, abbreviated schema
In the rankings
#2 oldest company in Hamme, Wholesale and retail trade sector#6 employer in Hamme, Wholesale and retail trade sector#8 company by total assets in Hamme, Wholesale and retail trade sector
Equity
-€992,548▼ 31.1%
2024 · -€757,014
Total assets
€4.9m▲ 10.5%
2024 · €4.5m
Net result
-€235,534▼ 1,372%
2024 · -€16,004
Working capital
-€4.7m▼ 18.4%
2024 · -€4.0m
Trend over the years
Click a name to add, emphasise or remove a line.Band: the middle half (P25 to P75) of NACE 47, Retail trade, each year against the same schema; no band under 30 filings. Dashed line: the median.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20212022202320242025
Operating result€155,096▲ 162%€54,640▼ 64.8%€115,148▲ 111%-€27,709-€243,377▼ 778%
Net result€156,837above the sector's middle half▲ 160%€56,560within the sector's middle half▼ 63.9%€117,025within the sector's middle half▲ 107%-€16,004below the sector's middle half-€235,534below the sector's middle half▼ 1,372%
Equity-€914,595below the sector's middle half▲ 14.6%-€858,035below the sector's middle half▲ 6.2%-€741,010below the sector's middle half▲ 13.6%-€757,014below the sector's middle half▼ 2.2%-€992,548below the sector's middle half▼ 31.1%
Total assets€3.7mabove the sector's middle half▼ 5.4%€3.8mabove the sector's middle half▲ 1.7%€3.6mabove the sector's middle half▼ 4.7%€4.5mabove the sector's middle half▲ 23.4%€4.9mabove the sector's middle half▲ 10.5%
Debt€4.6m▼ 7.4%€4.6m▲ 0.2%€4.3m▼ 6.4%€5.2m▲ 19.8%€5.9m▲ 13.5%
Working capital-€3.6m▲ 10.1%-€3.5m▲ 2.9%-€3.2m▲ 10.0%-€4.0m▼ 26.2%-€4.7m▼ 18.4%
Solvency-24.6%below the sector's middle half▲ 2.7pp-22.7%below the sector's middle half▲ 1.9pp-20.5%below the sector's middle half▲ 2.1pp-17.0%below the sector's middle half▲ 3.5pp-20.2%below the sector's middle half▼ 3.2pp
Staff (FTE)24.2above the sector's middle half▲ 0.4%24.2above the sector's middle half=24.3above the sector's middle half▲ 0.4%21.2above the sector's middle half▼ 12.8%16.5above the sector's middle half▼ 22.2%
above
within
below
the middle half (P25 to P75) of NACE 47, Retail trade, each year against the same schema; no band under 30 filings.
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result stays negative: a loss of €243,377 in 2025 against €27,709 in 2024; the loss grows and 2025 has the lowest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €4.9m
Fixed assets
€3.7m ▲ 15.4%
Current assets
€1.2m ▼ 2.5%
Key figures and ratios
EBITDA
€167,347▼
2024 · €285,770
Cash flow
€175,190▼
2024 · €297,475
Current ratio
0.20▼
2024 · 0.23
Quick ratio
0.10▼
2024 · 0.11
Debt to equity
-5.96▲
2024 · -6.88
ROA
-4.8%▼
2024 · -0.4%
Interest coverage
199.53▼
2024 · 475.14
Debt ≤ 1 year
€5.9m▲
2024 · €5.2m
Income taxes
€187▼
2024 · €204
Staff costs
€791,193▼
2024 · €861,291
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observationOf the 1,242 companies that looked in July 2024 the way this one looks now, 1.7% went bankrupt within 24 months and 93% are still going.
- Small
- 20 years or older
- negative equity
- a small loss
1.7%
went bankrupt
3.9%
stopped otherwise
93%
still going
A further 1.9% stopped, but we cannot tell whether within those 24 months.
For this company itself Checked computes a bankruptcy probability of 0.5% over twelve months; the group does not contradict it.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,058 companies of July 2024 its group's bankruptcy share. Expected: 1.5%; actually bankrupt within 24 months: 1.6%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.4% |
| 3 | 0.5% | 0.5% |
| 4 | 0.6% | 0.7% |
| 5 | 0.8% | 0.9% |
| 6 | 1.2% | 1.3% |
| 7 | 1.5% | 1.6% |
| 8 | 1.7% | 1.7% |
| 9 | 2.7% | 2.8% |
| 10 | 5.3% | 5.7% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 1,242 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Annual accounts
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Non-recurring operating income76A | - | €6,942 | €392 | - | - | - |
| Remuneration, social security and pensions62 | €895,699 | €825,894 | €840,830 | €861,291 | €791,193 | ▼ 8.1% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €276,835 | €276,736 | €269,698 | €313,479 | €410,724 | ▲ 31.0% |
| Other operating charges640/8 | €8,713 | €14,053 | €15,335 | €9,829 | €9,810 | ▼ 0.2% |
| Gross operating margin9900 | €1.3m | €1.2m | €1.2m | €1.2m | €968,350 | ▼ 16.3% |
| Operating profit (loss)9901 | €155,096 | €54,640 | €115,148 | -€27,709 | -€243,377 | ▼ 778% |
| Financial income75/76B | €2,666 | €2,604 | €2,506 | €12,509 | €8,869 | ▼ 29.1% |
| Recurring financial income75 | €2,666 | €2,604 | €2,506 | €12,509 | €8,869 | ▼ 29.1% |
| Financial charges65/66B | €445 | €463 | €529 | €601 | €839 | ▲ 39.4% |
| Recurring financial charges65 | €445 | €463 | €529 | €601 | €839 | ▲ 39.4% |
| Profit (loss) for the period before taxes9903 | €157,317 | €56,781 | €117,125 | -€15,801 | -€235,347 | ▼ 1,389% |
| Income taxes67/77 | €480 | €221 | €100 | €204 | €187 | ▼ 8.0% |
| Profit (loss) for the period9904 | €156,837 | €56,560 | €117,025 | -€16,004 | -€235,534 | ▼ 1,372% |
| Profit (loss) for the period to be appropriated9905 | €156,837 | €56,560 | €117,025 | -€16,004 | -€235,534 | ▼ 1,372% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €3.7m | €3.8m | €3.6m | €4.5m | €4.9m | ▲ 10.5% |
| Fixed assets21/28 | €2.7m | €2.7m | €2.4m | €3.2m | €3.7m | ▲ 15.4% |
| Tangible fixed assets22/27 | €2.7m | €2.7m | €2.4m | €3.2m | €3.7m | ▲ 15.4% |
| Land and buildings22 | €2.1m | €2.1m | €2.0m | €1.9m | €1.8m | ▼ 5.6% |
| Plant, machinery and equipment23 | €530,593 | €556,388 | €424,825 | €1.3m | €2.0m | ▲ 45.3% |
| Furniture and vehicles24 | €38,492 | €29,886 | €23,868 | €17,077 | €11,414 | ▼ 33.2% |
| Current assets29/58 | €1.0m | €1.1m | €1.2m | €1.2m | €1.2m | ▼ 2.5% |
| Stocks and contracts in progress3 | €634,378 | €734,377 | €686,950 | €649,193 | €609,871 | ▼ 6.1% |
| Stocks30/36 | €634,378 | €734,377 | €686,950 | €649,193 | €609,871 | ▼ 6.1% |
| Amounts receivable within one year40/41 | €371,733 | €375,466 | €488,325 | €556,751 | €565,742 | ▲ 1.6% |
| Trade receivables40 | €371,733 | €365,900 | €488,325 | €556,751 | €565,742 | ▲ 1.6% |
| Other amounts receivable41 | - | €9,566 | - | - | - | - |
| Cash at bank and in hand54/58 | €2,943 | €8,981 | €3,836 | €4,481 | €4,220 | ▼ 5.8% |
| Deferred charges and accrued income490/1 | - | €5,399 | - | - | - | - |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €3.7m | €3.8m | €3.6m | €4.5m | €4.9m | ▲ 10.5% |
| Equity10/15 | -€914,595 | -€858,035 | -€741,010 | -€757,014 | -€992,548 | ▼ 31.1% |
| Contributions10/11 | €568,600 | €568,600 | €568,600 | €568,600 | €568,600 | = |
| Reserves13 | €292,986 | €292,986 | €292,986 | €292,986 | €292,986 | = |
| Distributable reserves133 | €292,986 | €292,986 | €292,986 | €292,986 | €292,986 | = |
| Profit (loss) carried forward14 | -€1.8m | -€1.7m | -€1.6m | -€1.6m | -€1.9m | ▼ 14.6% |
| Amounts payable17/49 | €4.6m | €4.6m | €4.3m | €5.2m | €5.9m | ▲ 13.5% |
| Amounts payable within one year42/48 | €4.6m | €4.6m | €4.3m | €5.2m | €5.9m | ▲ 13.5% |
| Trade debts44 | €123,792 | €320,078 | €241,057 | €338,029 | €1.2m | ▲ 267% |
| Suppliers440/4 | €123,792 | €320,078 | €241,057 | €338,029 | €1.2m | ▲ 267% |
| Taxes, remuneration and social security45 | €149,207 | €93,681 | €109,663 | €104,794 | €97,515 | ▼ 6.9% |
| Taxes450/3 | €23,811 | €3,484 | €10,662 | €7,663 | €4,635 | ▼ 39.5% |
| Remuneration and social security454/9 | €125,396 | €90,197 | €99,001 | €97,132 | €92,879 | ▼ 4.4% |
| Other amounts payable47/48 | €4.4m | €4.2m | €4.0m | €4.8m | €4.6m | ▼ 4.0% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €156,837 | €56,560 | €117,025 | -€16,004 | -€235,534 | ▼ 1,372% |
| + Depreciation and write-downs630 | €276,835 | €276,736 | €269,698 | €313,479 | €410,724 | ▲ 31.0% |
| Operating cash flow (approximation) | €433,672 | €333,296 | €386,723 | €297,475 | €175,190 | ▼ 41.1% |
| Investment in fixed assets (approximation) | - | -€226,521 | -€35,343 | -€1.1m | -€910,114 | ▲ 19.3% |
| Change in cash | - | €6,038 | -€5,145 | €645 | -€261 | ▼ 141% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
24-07
State Gazette act
Resignation: BV ALEXO (director)Appointment: BV KST Pharma (director) · Reappointment: BV SODIAP (managing director) · Permanent representatives: Olivier Delaere, Koen Straetmans and Tom Goderis8 facts ▸
State Gazette act
Resignation: BV ALEXO (director)
Appointment: BV KST Pharma (director) · Reappointment: BV SODIAP (managing director) · Permanent representatives: Olivier Delaere, Koen Straetmans and Tom Goderis8 facts ▸
- General meeting, 19-05-2026
- Board meeting, 19-05-2026
- Director resignation, BV ALEXO (director)
- Director appointment, BV KST Pharma (director)
- Director reappointment, BV SODIAP (managing director)
- Permanent representative, Olivier Delaere (permanent representative)
- Permanent representative, Koen Straetmans (permanent representative)
- Permanent representative, Tom Goderis (permanent representative)
12-05
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
2025
16-06
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
11-06
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2023
09-06
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2022
07-06
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2021
31-12
Financial
Highest result since 2018net €156,837 ▲160%
Operating result €155,096, net result €156,837, both a record.
14-06
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
2020
31-12
Financial
Back to profitnet €60,333
Net result €60,333 after 2 loss-making years.
13-07
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
2019
09-07
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema
2018
28-06
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema
2017
10-07
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
1 of 8 acts read
About the unread acts
Of the 8 Belgian State Gazette acts we know for this company, 1 has been read. The other 7 have not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
1 director, 1 in day-to-day management, last change in 2026
Board 1
BV KST Pharma
CurrentDirector · since 19-05-2026 · Legal entity · perm. rep.: Koen Straetmans
Day-to-day management 1
BV SODIAP
CurrentManaging director · Legal entity · perm. rep.: Tom Goderis
Permanent representatives 2
Koen Straetmans
CurrentPermanent representative · since 19-05-2026 · for BV KST Pharma
Tom Goderis
CurrentPermanent representative · for BV SODIAP
Derived from published Gazette acts. The CBE keeps the official list of function holders; we do not read it, so the two can differ.
See the function holders in the CBE →
Not every act has been read: a resignation may be missing here
7 of this company's 8 Belgian State Gazette acts have not been read yet. Appointments and resignations recorded in them are missing above: a director who resigned there may therefore still show here as sitting. The acts are in the Timeline.
Location & real-estate footprint
Registered office, Hamme (Vl.) · 1 establishment unit since 1961
Ground area
499 m²
Building footprint
116 m²
Volume, LiDAR
1,100 m³
Parcel 42452B0229/00W002, Flanders · tallest building 15.3 m, ±4 floors. Linked by address, not a title deed.
1 establishment unit
apotheek HC Pharma
since 19612.006.218.831
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 42452B0229/00W002 | Flanders | 499 m² | 1 · 116 m² | 15.3 m · 4 fl. |
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Mandate history
3 people since 2026, 2 in office
- Board
- Day-to-day management
- began earlier
| Name | Functions and periods |
|---|---|
| BV KST Pharma |
|
| BV SODIAP |
|
| BV ALEXO |
|
Structure & network
Part of the group
PHARMACIE BIA
40 companies
Group, risk and exposure
Owners and holdings
1 ownerChain of control
- PHARMACIE BIA
- FEBELCO
- SODIAP
- HC Pharma
Highest known parent: PHARMACIE BIA. The sources do not say who stands above it.
Owners 1
- SODIAPparentSourceaccounts SODIAP 2025100%
Holdings 0
No holding stated in the accounts, acts or LEI register we read.
According to the annual accounts of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.
Connections & network
2 current directorsThe network starts from this company’s directors. Other companies they run appear here as nodes.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, scroll to zoom.
Public money · subsidies and aid
Flemish government
2022 to 2025 · 4 entries · 32,571 EUR awarded · 32,571 EUR paid| Year | Entries | awarded | paid |
|---|---|---|---|
| 2025 | 1 | 6,759 EUR | 6,759 EUR |
| 2024 | 1 | 6,550 EUR | 6,550 EUR |
| 2023 | 1 | 8,828 EUR | 8,828 EUR |
| 2022 | 1 | 10,434 EUR | 10,434 EUR |
Recognitions · licences · registrations
Food safety, FASFC
1 siteHamme (O.-Vl.)2.006.218.831
Similar companies · same sector, comparable size
Apotheek Hulsbosch
BE 0879.969.548
Hamont-Achel · FTE 16.7
Superphar
BE 0406.879.465
Namur · FTE 16.3
Pharmacie FOURMY
BE 0882.900.334
Silly · FTE 16.3
Apotheek Hildegard
BE 0428.847.688
Evere · FTE 16.8
Europhar
BE 0465.065.411
Genappe · FTE 16.1
Of 5,220 companies in sector 47730 we hold annual accounts for 3,862. 2,111 are within a factor 10 of this headcount. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPrivate limited company
Founded14-04-1961
Fiscal year end31-12
Activities, NACEBEL 2025
47730Retail sale of pharmaceutical products
E-invoicing
Reachable via Peppol
Peppol ID
0208:0405023993
Registered
06-06-2025
Register as of 27 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.